Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
Startup vendor FIRE1 completed patient enrollment in its U.S. early feasibility study for a heart failure remote monitoring device that directly measures fluid volume inside the IVC.
Cerebral protection devices, designed to limit the risk of stroke during transcatheter aortic valve replacement, may be especially helpful when patients undergo valve-in-valve TAVR.
